ArticleFuture oncology (London, England)2025
Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US.
Erin Mulvey et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.